List of Excipients in Branded Drug HYDROCORTISONE CREAM

« Back to Dashboard

Generic Drugs Containing HYDROCORTISONE CREAM

Company	Ingredient	NDC	Excipient
Direct_Rx	hydrocortisone cream	72189-554	CETYL ALCOHOL
Direct_Rx	hydrocortisone cream	72189-554	METHYLPARABEN
Direct_Rx	hydrocortisone cream	72189-554	PROPYLENE GLYCOL
Direct_Rx	hydrocortisone cream	72189-554	PROPYLPARABEN

What are the Most Frequently-Used Excipients in HYDROCORTISONE CREAM?

# Of NDCs	Excipient
1	BENZYL ALCOHOL
1	CETYL ALCOHOL
1	GLYCERIN
1	GLYCERYL MONOSTEARATE

Hydrocortisone Cream Excipient Strategy and Commercial Opportunities

Last updated: October 23, 2026

Hydrocortisone cream is a mature, low-cost topical corticosteroid market in which the active ingredient provides limited differentiation. Commercial value is concentrated in vehicle performance, skin tolerability, preservative systems, packaging, regulatory positioning, and targeted consumer segments. The strongest opportunities are low-irritancy formulations, cosmetically acceptable emulsions, preservative-free or low-preservative systems, pediatric and sensitive-skin products, and private-label platforms that can support multiple strengths and indications.

Hydrocortisone 0.5% and 1% products are widely available over the counter in the United States under FDA’s topical corticosteroid framework. Hydrocortisone 2.5% products are generally prescription products. The active ingredient is old and typically does not create meaningful composition-of-matter exclusivity. Patent value is more likely to arise from a specific formulation, delivery system, manufacturing process, package, or combination product than from hydrocortisone itself.

What is the commercial market for hydrocortisone cream?

Hydrocortisone cream is used for temporary relief of itching and inflammation associated with minor dermatoses, including eczema, insect bites, poison ivy, soaps, detergents, and other irritants. In the United States, nonprescription products generally contain 0.5% or 1% hydrocortisone, while prescription products may contain 2.5% hydrocortisone or use different hydrocortisone salts or esters.

Segment	Typical strength	Regulatory pathway	Primary buyer	Commercial profile
OTC mass market	0.5% or 1%	FDA OTC monograph pathway, where applicable	Consumers, retailers	High volume, low unit price
Store brand	0.5% or 1%	OTC monograph or authorized equivalent	Retailers and private-label marketers	Price-sensitive, contract-manufacturing driven
Prescription generic	Commonly 2.5%	ANDA or other approved application	Pharmacies, payers, physicians	Reimbursement and formulary driven
Premium sensitive-skin	Usually 1%	OTC pathway if compliant	Consumers with eczema-prone or reactive skin	Higher price, lower volume
Pediatric and family	Usually 0.5% or 1%	OTC pathway if compliant	Parents and caregivers	Requires strong tolerability and labeling discipline
Specialty delivery	Variable	Product-specific regulatory assessment	Dermatology and specialty retailers	Potentially differentiated, higher development cost

The market is fragmented across branded OTC products, retailer private labels, generic prescription products, pharmacy chains, online retailers, and dermatology-focused brands. Contract manufacturers can use one validated hydrocortisone cream platform to supply several labels, package sizes, and retail channels.

What excipients are used in hydrocortisone cream?

Hydrocortisone creams usually contain an oil-in-water emulsion. The aqueous phase supports hydration and ease of spreading, while the oil phase contributes occlusivity, emollience, and drug partitioning. The excipient system must maintain hydrocortisone uniformity, physical stability, microbial quality, skin tolerability, and acceptable sensory performance.

Core excipient classes

Excipient class	Common functions	Representative options
Purified water	Continuous phase and solvent	Purified water
Emollients	Reduce roughness and improve spreadability	Mineral oil, isopropyl myristate, caprylic/capric triglyceride
Occlusives	Reduce transepidermal water loss	Petrolatum, paraffin, mineral oil
Humectants	Retain water in the stratum corneum	Glycerin, propylene glycol, sorbitol
Emulsifiers	Stabilize oil-in-water emulsions	Glyceryl stearate, PEG stearates, polysorbates, fatty alcohol systems
Consistency agents	Build viscosity and body	Cetyl alcohol, stearyl alcohol, cetearyl alcohol, stearic acid
Suspending or rheology agents	Improve physical stability and flow	Carbomers, cellulose derivatives, xanthan gum
Preservatives	Control bacteria, yeast, and mold	Phenoxyethanol, parabens, benzoic acid systems, sorbates
Chelating agents	Bind trace metals and support preservation	Disodium EDTA
pH adjusters	Control stability, preservative activity, and skin feel	Citric acid, sodium citrate, sodium hydroxide
Antioxidants	Limit oxidative degradation	Tocopherol, sodium metabisulfite, butylated hydroxytoluene where appropriate
Solubilizers	Improve incorporation of selected ingredients	Propylene glycol, polyethylene glycols
Fragrance and colorants	Improve sensory or visual identity	Optional, generally unfavorable for sensitive-skin positioning

The final selection depends on the target product profile. A low-cost retail cream may favor conventional mineral oil, stearic acid, fatty alcohols, and a standard preservative system. A premium sensitive-skin product may reduce fragrance, colorants, volatile solvents, and sensitizing preservatives while increasing the role of glycerin, petrolatum, barrier lipids, or newer emollients.

How should an excipient strategy be designed for hydrocortisone cream?

A successful excipient strategy starts with a defined target product profile rather than with a preferred ingredient list. The main design variables are potency uniformity, skin tolerability, preservation, sensory profile, package compatibility, and manufacturing cost.

1. Select the vehicle based on clinical and commercial positioning

An oil-in-water cream is usually the most commercially versatile vehicle. It is easier to spread and wash off than an ointment and is more cosmetically acceptable for daytime use. An ointment provides greater occlusion and may be better suited to very dry or thickened lesions, but it can be perceived as greasy.

A water-in-oil cream can provide stronger occlusion and improved resistance to wash-off, although it may be less acceptable for facial use or large-area application. A lotion or gel may appeal to consumers seeking rapid absorption, but the lower occlusivity can reduce perceived moisturization and may increase sting if alcohol or high solvent levels are used.

2. Manage hydrocortisone solubility and uniformity

Hydrocortisone has limited water solubility. Formulators must determine whether the target system should be a solution, suspension, or partially solubilized dispersion. Propylene glycol and polyethylene glycol systems may assist incorporation, but excessive solvent can increase irritation or alter the drug’s partitioning into skin.

Uniformity is a critical risk because a low-dose topical product can show meaningful content variability if hydrocortisone is inadequately dispersed. Particle-size distribution, milling, premixing, order of addition, homogenization, and cooling conditions can affect dose uniformity and release.

3. Build a preservative strategy around the final formulation

Creams contain water and are vulnerable to microbial contamination. The preservative system must be assessed in the finished product, not only in the bulk phase. Emulsions can reduce the effective concentration of a preservative by partitioning it between oil and water phases.

Preservative efficacy testing, microbial limits, bulk-hold studies, preservative compatibility, and package-use simulations are central development requirements. A preservative-free product may be possible with an appropriate package, such as a unit-dose container or airless system, but the package does not eliminate the need for robust microbiological control.

4. Control pH without compromising skin feel

The target pH should support hydrocortisone stability, preservative effectiveness, emulsion integrity, and tolerability. A product that is excessively acidic or alkaline can sting compromised skin. Buffer capacity should be controlled because strong buffering may limit the formulation’s ability to accommodate minor raw-material variation.

5. Avoid unnecessary sensitizers

Fragrance is not needed for pharmacologic performance and can weaken a sensitive-skin value proposition. Certain preservatives, botanicals, essential oils, and colorants can also increase the risk of irritation or sensitization. A fragrance-free, dye-free, and low-allergen formulation has a clearer commercial position for eczema-prone consumers.

What formulation patents can protect hydrocortisone cream?

Hydrocortisone itself is a long-established active ingredient. New patent protection generally must arise from a novel and non-obvious formulation, manufacturing process, delivery system, package, or therapeutic use.

Potential claim categories include:

Patent area	Potential claim subject matter	Commercial value
Composition	Defined ratios of emollients, emulsifiers, solvents, and rheology agents	Moderate if performance is demonstrably improved
Particle engineering	Hydrocortisone particle size, crystalline form, or dispersion method	Moderate to high if linked to release or uniformity
Release profile	Controlled delivery or reduced burst release	Potentially high in specialty products
Skin penetration	Enhanced delivery with a defined excipient system	High regulatory and safety burden
Low-irritancy system	Preservative-reduced or fragrance-free composition with validated stability	Moderate, but difficult to defend broadly
Packaging	Airless, metered-dose, unit-dose, or contamination-limiting package	Moderate, subject to design-around risk
Manufacturing	Mixing, homogenization, cooling, or aseptic process parameters	Moderate if process-specific and difficult to replicate
Combination therapy	Hydrocortisone with an antimicrobial, antifungal, barrier ingredient, or keratolytic	Variable and subject to regulatory requirements
Method of use	Treatment of a defined condition or patient population	Usually narrower and dependent on clinical support

A formulation patent is stronger when it claims a measurable technical result, such as improved stability, dose uniformity, reduced degradation, enhanced delivery, lower irritation, or improved package-use microbiological performance. Broad claims that merely list familiar excipients are more vulnerable to obviousness challenges.

What is the FDA regulatory status of hydrocortisone cream?

In the United States, OTC hydrocortisone products must comply with the applicable FDA topical corticosteroid monograph requirements, including active-ingredient concentration, labeling, indications, warnings, directions, dosage form, and other conditions of marketing. FDA’s OTC Monograph M017 addresses topical corticosteroids, including hydrocortisone products marketed under the monograph framework (FDA, n.d.-a).

Prescription hydrocortisone creams are approved drug products and may be submitted as abbreviated new drug applications when the proposed product meets the relevant requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling. Hydrocortisone cream does not generally present the same development barriers as complex dermatologic products such as nanosuspensions, liposomal systems, or highly specialized delivery platforms.

What FDA quality issues matter most?

The most important quality attributes include:

• Assay and content uniformity
• Particle-size distribution and dispersion
• In vitro release rate
• Microbial limits
• Preservative effectiveness
• Emulsion stability
• Viscosity and rheology
• pH
• Appearance, odor, and phase separation
• Container-closure compatibility
• Net contents and fill-weight uniformity

For semisolid products, FDA’s product-specific guidance and topical dermatologic development expectations make in vitro release testing and comparative characterization important tools for generic and reformulated products (FDA, n.d.-b).

What is the Orange Book and patent status of hydrocortisone cream?

Hydrocortisone cream has limited patent-based exclusivity because the active ingredient has been marketed for decades. Orange Book relevance depends on the specific approved prescription product, sponsor, strength, dosage form, and listed patents. OTC monograph products do not generally rely on Orange Book patent listings in the same way as prescription products.

A commercial review should separate four categories:

1. Hydrocortisone as an old active ingredient.
2. Specific prescription products and their approved labeling.
3. Formulation or delivery patents owned by individual sponsors.
4. Patent listings and regulatory exclusivity associated with a particular approved application.

No general hydrocortisone cream patent should be treated as a market-wide barrier. A competitor may design around a particular excipient ratio, package, or manufacturing claim while retaining the same active ingredient and indication.

When does hydrocortisone cream lose exclusivity?

For most hydrocortisone cream products, practical exclusivity has already expired. The commercial question is therefore usually not when hydrocortisone loses exclusivity, but whether a new formulation can obtain meaningful protection.

Exclusivity type	Relevance to hydrocortisone cream
Composition-of-matter patent	Generally exhausted for the old active ingredient
Regulatory exclusivity for a new drug	Product-specific and uncommon for conventional cream
Formulation patent	Possible for a novel, supported composition
Method-of-use patent	Possible but usually narrow
Package patent	Possible but susceptible to design-around
OTC monograph protection	Regulatory compliance pathway, not market exclusivity
Trade secret	Relevant to process parameters and manufacturing know-how
Trademark and trade dress	Often more commercially important than patent rights in OTC retail

Paragraph IV litigation may arise if a sponsor lists a formulation or method patent against an ANDA applicant. For ordinary hydrocortisone cream, litigation risk is generally lower than for newer dermatology products because multiple suppliers and established formulations limit the ability to sustain broad exclusivity.

Which companies are challenging hydrocortisone cream patents?

Hydrocortisone cream is a genericized and highly competitive category. Challenges typically arise from generic manufacturers, private-label suppliers, contract manufacturers, and vertically integrated consumer-health companies. The relevant parties vary by strength, dosage form, brand, and approved application.

Because patent activity is product-specific, a defensible assessment must identify the exact reference listed drug, application number, Orange Book entries, and asserted patents. A category-level statement that a particular company is challenging "hydrocortisone cream patents" is not reliable without linking the challenge to a defined product and docket.

For OTC products, competition is more likely to occur through monograph compliance, price, retail distribution, brand recognition, packaging, and formulation claims than through Paragraph IV litigation.

What commercial opportunities exist for hydrocortisone cream?

Sensitive-skin and eczema-oriented products

A fragrance-free cream with a short excipient list, high skin tolerability, and a non-greasy finish can command a premium over conventional store-brand products. The product should avoid unsupported claims such as repairing the skin barrier or treating eczema unless the labeling and evidence support those claims.

Preservative-reduced and package-enabled products

Airless pumps, metered-dose dispensers, and unit-dose formats can support a low-preservative positioning. These packages also create opportunities for improved dose control, reduced contamination during repeated use, and premium pricing.

Pediatric and family use

Parents often prioritize low fragrance, low sting, easy application, and clear dosing instructions. A family platform can include 0.5% hydrocortisone, a moisturizer-only companion product, and a larger-format body product. Regulatory labeling must distinguish cosmetic moisturization claims from drug claims.

Combination and adjunctive products

Potential product families include hydrocortisone with barrier-supportive excipients, moisturizers, keratolytics, or antimicrobial ingredients. Combination products increase regulatory and safety complexity. Antifungal or antibacterial combinations require particular care because steroid use can mask or worsen certain infections.

Retailer private-label platforms

Private-label growth depends on manufacturing flexibility, low minimum order quantities, validated stability, packaging options, and the ability to produce multiple strengths. A single emulsion platform can be adapted for national brands, store brands, online sellers, and dermatology-focused labels.

Regional and geographic expansion

OTC regulatory treatment differs by jurisdiction. The United States, European Union, United Kingdom, Canada, Australia, and emerging markets vary in permitted strengths, prescription status, labeling, excipient restrictions, and registration requirements. A formulation designed for multiple markets should avoid unnecessary ingredients that trigger regional restrictions or consumer concerns.

How strong is the patent estate for hydrocortisone cream?

The baseline patent estate for conventional hydrocortisone cream is weak. The active ingredient is commoditized, numerous equivalent formulations are available, and many excipients are standard pharmaceutical ingredients. Protection becomes stronger only where the sponsor can demonstrate a technically meaningful improvement that is difficult to reproduce without practicing the claims.

Asset type	Relative strength	Main weakness
Conventional hydrocortisone cream	Low	Easy substitution and established prior art
Novel low-irritancy composition	Moderate	Functional overlap with known excipient systems
Controlled-release topical system	Moderate to high	Higher development and proof burden
Metered-dose package	Moderate	Straightforward design-around
Manufacturing process	Moderate	Enforcement may be difficult without discovery
Brand and trade dress	Moderate in OTC retail	Does not prevent generic substitution
Proprietary combination product	Variable	Regulatory and clinical complexity

Trade secrets may provide better practical protection than patents for mixing order, temperature control, homogenization, particle dispersion, filling parameters, and scale-up know-how. Those protections do not prevent independent development but can reduce manufacturing failures and improve consistency.

What generic launch risks exist for hydrocortisone cream?

Generic launch risk is high for conventional products because:

• The active ingredient is widely available.
• Numerous excipient alternatives exist.
• Conventional cream technology is well understood.
• Retailers can switch among suppliers.
• Brand loyalty is limited for low-price products.
• Patent barriers are usually narrow or absent.
• Contract manufacturers can scale established formulas quickly.

Risk increases for premium products if the sponsor has a defensible package, a differentiated sensory profile, strong consumer recognition, or evidence supporting superior skin tolerability. Even then, competitors can often launch an equivalent product with a different excipient system.

What licensing deals are relevant to hydrocortisone cream?

Large licensing transactions are uncommon for conventional hydrocortisone cream. Commercial arrangements are more likely to involve:

• Contract manufacturing and supply agreements
• Private-label development
• Trademark licensing
• Distribution rights
• Packaging technology licenses
• Co-development of specialty topical delivery systems
• Regional rights for branded dermatology products

The most valuable licensable asset is usually a differentiated delivery technology rather than hydrocortisone itself. A license should define ownership of formulation improvements, process changes, analytical methods, regulatory filings, package designs, and market-specific registrations.

Key Takeaways

• Hydrocortisone cream is a mature, low-exclusivity market.
• Commercial differentiation depends primarily on excipients, vehicle performance, packaging, tolerability, and brand positioning.
• Oil-in-water creams offer the broadest balance of spreadability, washability, manufacturing familiarity, and consumer acceptance.
• Fragrance-free, low-irritancy, pediatric, sensitive-skin, and preservative-reduced products offer the clearest premium opportunities.
• Conventional hydrocortisone cream has limited patent strength; formulation, delivery, package, and process claims are the main protection routes.
• Generic launch risk is high because the active ingredient and basic cream technology are widely available.
• Trade secrets, manufacturing execution, package engineering, and retail distribution may provide more practical value than broad patent claims.
• OTC monograph compliance is central for 0.5% and 1% products, while prescription products require application-specific regulatory analysis.
• Combination products can expand the market but create greater safety, clinical, labeling, and regulatory risk.

FAQs

Can hydrocortisone cream be formulated without parabens?

Yes. A paraben-free product can use another validated preservative system, a preservative-reduced design, or a package that limits repeated contamination. The finished product still requires appropriate microbiological testing and preservative-efficacy support.

Which excipient improves hydrocortisone cream penetration?

Propylene glycol and certain emollient or solvent systems can influence drug partitioning and skin delivery. The effect depends on concentration, vehicle structure, skin condition, and hydrocortisone’s physical state. No single excipient guarantees superior penetration.

Is petrolatum compatible with hydrocortisone cream?

Yes. Petrolatum is widely used as an occlusive and emollient. In an oil-in-water cream, it must be properly incorporated into the oil phase and balanced against viscosity, greasiness, emulsion stability, and consumer preference.

Can hydrocortisone cream use a cosmetic claim strategy?

A product containing hydrocortisone and marketed for temporary relief of itching or inflammation is a drug product. Cosmetic claims may be used for a companion moisturizer, but claims that imply treatment, prevention, or relief of disease can trigger drug regulation.

What is the best package for premium hydrocortisone cream?

An airless pump or metered-dose package can support dose consistency, lower contamination risk, and premium positioning. Tube packaging remains more economical and familiar, particularly for mass-market and generic products.

References

1. U.S. Food and Drug Administration. (n.d.-a). OTC Monograph M017: Topical corticosteroids. https://www.accessdata.fda.gov/

2. U.S. Food and Drug Administration. (n.d.-b). Draft guidance for industry: In vitro release test studies for topical drug products submitted in ANDAs. https://www.fda.gov/

3. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (n.d.-d). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm